{"id":390895,"date":"2017-10-04T00:00:00","date_gmt":"2017-10-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfon0007-2017-biopharma-acute-lymphoblastic-leukemia-niche-rare-disease-landscape-forecast-us-eu5-2017\/"},"modified":"2026-05-01T23:42:18","modified_gmt":"2026-05-01T23:42:18","slug":"nrlfon0007-2017-biopharma-acute-lymphoblastic-leukemia-niche-rare-disease-landscape-forecast-us-eu5-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfon0007-2017-biopharma-acute-lymphoblastic-leukemia-niche-rare-disease-landscape-forecast-us-eu5-2017\/","title":{"rendered":"Acute Lymphoblastic Leukemia | Niche &#038; Rare Disease Landscape &#038; Forecast | US\/EU5 | 2017"},"content":{"rendered":"<p>Acute lymphoblastic leukemia (<abbr data-original-title=\"acute lymphoblastic leukemia\" title=\"\">ALL<\/abbr>) is a cancer of the white blood cells. Over the last few years, a number of agents have been launched that have improved treatment outcomes for patients with\u00a0<abbr data-original-title=\"acute lymphoblastic leukemia\" title=\"\">ALL<\/abbr>. These agents include monoclonal antibodies to CD19 (Amgen\u2019s Blincyto) and CD20 (Roche\/Genentech\u2019s Rituxan\/MabThera); new drugs for T-cell\u00a0<abbr data-original-title=\"acute lymphoblastic leukemia\" title=\"\">ALL<\/abbr>\u00a0(e.g., Novartis\u2019s Arranon); and\u00a0<abbr data-original-title=\"tyrosine kinase inhibitor\" title=\"\">TKI<\/abbr>\u00a0agents for Philadelphia chromosome-positive (<abbr data-original-title=\"Philadelphia chromosome-positive\" title=\"\">Ph+<\/abbr>)\u00a0<abbr data-original-title=\"acute lymphoblastic leukemia\" title=\"\">ALL<\/abbr>\u00a0(e.g., Novartis\u2019s Gleevec,\u00a0<abbr data-original-title=\"Bristol-Myers Squibb\" title=\"\">BMS<\/abbr>\u2019s Sprycel, Ariad Pharmaceutical\u2019s Iclusig). Nonetheless, chemotherapies remain the backbone of first-line treatment for\u00a0<abbr data-original-title=\"acute lymphoblastic leukemia\" title=\"\">ALL<\/abbr>. Targeted agents in development\u2014including novel kinase inhibitors, proteasome inhibitors, and immunomodulatory agents, such as chimeric antigen receptor T-cell (<abbr data-original-title=\"chimeric antigen receptor\" title=\"\">CAR<\/abbr>-T) therapies\u2014hold promise of providing\u00a0<abbr data-original-title=\"acute lymphoblastic leukemia\" title=\"\">ALL<\/abbr>\u00a0patients with additional treatment options.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>What is the size of the U.S. and\u00a0<abbr data-original-title=\"France, Germany, Italy, Spain, UK\" title=\"\">EU5<\/abbr>\u00a0<abbr data-original-title=\"acute lymphoblastic leukemia\" title=\"\">ALL<\/abbr>\u00a0patient populations, and how will drug treatment rates change over the ten-year forecast period? What are the drug-treatable populations of most commercial interest?<\/li>\n<li>What is the current medical practice and management for\u00a0<abbr data-original-title=\"acute lymphoblastic leukemia\" title=\"\">ALL<\/abbr>\u00a0in the markets under study? What are interviewed experts\u2019 insights on current treatment options? What clinical needs remain unfulfilled? What is thought-leader opinion of the\u00a0<abbr data-original-title=\"chimeric antigen receptor\" title=\"\">CAR<\/abbr>-Ts and other emerging therapies? How will these therapies fit into the\u00a0<abbr data-original-title=\"acute lymphoblastic leukemia\" title=\"\">ALL<\/abbr>\u00a0treatment algorithm in the future?<\/li>\n<li>How have the entry of biosimilar rituximab in the\u00a0<abbr data-original-title=\"France, Germany, Italy, Spain, UK\" title=\"\">EU5<\/abbr>\u00a0and the generic entry of imatinib in the U.S. and\u00a0<abbr data-original-title=\"France, Germany, Italy, Spain, UK\" title=\"\">EU5<\/abbr>\u00a0affected the\u00a0<abbr data-original-title=\"acute lymphoblastic leukemia\" title=\"\">ALL<\/abbr>\u00a0market?<\/li>\n<\/ul>\n<p><strong>Scope:<\/strong><\/p>\n<p><b>Market covered:\u00a0<\/b>United States, France, Germany, Italy, Spain, and the United Kingdom.<\/p>\n<p><b>Primary research:\u00a0<\/b>Six country-specific interviews with thought leaders (medical oncologist-hematologists).<\/p>\n<p><b>Epidemiology:\u00a0<\/b>Diagnosed incident cases of\u00a0<abbr data-original-title=\"acute lymphoblastic leukemia\" title=\"\">ALL<\/abbr>\u00a0subpopulations; clinical and market-relevant drug-treatable populations.<\/p>\n<p><b>Population segments in market forecast:\u00a0<\/b>First-line adult and pediatric\u00a0<abbr data-original-title=\"acute lymphoblastic leukemia\" title=\"\">ALL<\/abbr>; relapsed\/refractory adult and pediatric\u00a0<abbr data-original-title=\"acute lymphoblastic leukemia\" title=\"\">ALL<\/abbr>.<\/p>\n<p><b>Emerging therapies:\u00a0<\/b>Phase III: 3 drugs; Phase II: 3 drugs.<\/p>\n<p><strong>Product Description:\u00a0<\/strong>Niche &#038; Rare Disease Landscape &#038; Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390895","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-acute-lymphoblastic-leukemia","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390895","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390895\/revisions"}],"predecessor-version":[{"id":576812,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390895\/revisions\/576812"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390895"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}